MetaCap

CytomX Therapeutics Inc. Company Profile

NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.03-0.02 (-0.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CytomX Therapeutics at a glance

CytomX Therapeutics Inc. (NASDAQ: CTMX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in South San Francisco, CA. CytomX Therapeutics is led by Dr. Sean A. McCarthy DPHIL and employs about 69 people. The company's shares have traded publicly since 2015.

At a market capitalization of $446.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001501989, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does CytomX Therapeutics do?

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Business description based on the company's public filings.

Company information

Legal name
CytomX Therapeutics Inc.
Ticker
NASDAQ: CTMX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Sean A. McCarthy DPHIL
Employees
69
Headquarters
151 Oyster Point Boulevard, South San Francisco, CA, United States
Phone
650 515 3185
Website
cytomx.com
IPO year
2015
Market cap
$446.91M
SEC CIK
0001501989
Latest annual report
10-K · Mar 16, 2026

Companies similar to CytomX Therapeutics

CTMX peer companies
CompanyPrice% ChgMarket capCompare
KMDAKamada Ltd.7.74-1.15%$446.85Mvs CTMX
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs CTMX
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs CTMX
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs CTMX
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs CTMX
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs CTMX
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs CTMX
NGNENeurogene Inc.22.15-3.40%$458.53Mvs CTMX

Related